Skip to content

Endoscopic Ultrasound-guided Fine-needle Aspiration of Solid Pancreatic Lesions With Rapid Staining of Cytological Smears Followed by Whole Slide Scanning and Artificial Intelligence Diagnosis: A Prospective, Multicenter Study.

内镜超声穿刺胰腺实性占位细胞涂片快速染色后全玻片扫描及人工智能诊断:一项前瞻性、多中心研究

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06824909
Enrollment
1500
Registered
2025-02-13
Start date
2024-12-31
Completion date
2027-06-30
Last updated
2025-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Disease

Brief summary

The objective of this observational study is to investigate whether the self-developed whole slide scanning and artificial intelligence diagnostic system for pancreatic solid lesion puncture cytopathology (hereinafter referred to as the Zhiying Shunxi ROSE-AI diagnostic system) can promptly and accurately diagnose solid pancreatic lesions (SPLs). The main question it aims to answer is: By utilizing optical imaging technology to capture RGB images of Diff-Quik stained smears from pancreatic punctures, can the development of artificial intelligence algorithms assist in differentiating solid pancreatic space-occupying diseases (such as pancreatic ductal adenocarcinoma, pancreatic neuroendocrine tumors, and non-neoplastic benign lesions)? Researchers will compare the diagnoses of SPLs made by the ROSE-AI system with the actual pathological diagnoses of the SPLs themselves to determine whether the ROSE-AI system can effectively diagnose SPLs.

Interventions

DEVICEROSE-AI diagnostic system

All samples were obtained due to the necessity for disease treatment and in accordance with routine clinical workflows. After the pathological diagnoses were confirmed by the pathology departments of the hospitals affiliated with the respective endoscopic centers, the eligible pancreatic puncture Diff-Quik stained smears were borrowed and transferred to Ruijin Hospital Affiliated to School of Medicine, Shanghai Jiao Tong University. There, the self-developed Zhiying Shunxi system was used to capture corresponding traditional light microscope RGB images. After the imaging was completed, all specimens were returned to the endoscopic centers from which they originated. Using the RGB images as input, an artificial intelligence algorithm was developed to assist in differentiating solid pancreatic lesions.

Sponsors

Second Affiliated Hospital of Soochow University
CollaboratorOTHER
Fudan University
CollaboratorOTHER
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
CollaboratorOTHER
The Third Xiangya Hospital of Central South University
CollaboratorOTHER
Shanghai 10th People's Hospital
CollaboratorOTHER
Affiliated Hospital of Jiangnan University
CollaboratorOTHER
Jiangyin People's Hospital
CollaboratorOTHER
Ruijin Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* A dated and signed informed consent form A commitment to abide by the research procedures and cooperate throughout the entire study Subjects aged 18 and above, regardless of gender Diagnosis or suspicion of a solid pancreatic space-occupying lesion based on imaging studies (B-mode ultrasound, CT, or MRI)

Exclusion criteria

* Unable or refusing to sign the informed consent form Unable to suspend anticoagulation/antiplatelet therapy Pregnant or lactating Having a mental illness or other medical conditions that are unsuitable for undergoing FNA/B biopsy Presence of coagulation disorders (PLT \< 50 × 10\^3/μl, INR \> 1.5) Pancreatic cystic lesions Non-diagnostic EUS-FNA/B specimens Having less than 8 microscopic fields of interest (ROI) in the digital pathology images of the entire Diff-Quik smear slide

Design outcomes

Primary

MeasureTime frameDescription
Accuracythrough study completion, an average of 2 yearsAccuracy = (TP + TN) / (TP + FP + FN + TN)

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026